Oncology Hero 11 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials recently authorised in Europe. A phase II, multicenter, open-label, personalized medicine, tumor agnostic platform trial evaluating the anti-tumor activity of antibody-based therapies in metastatic cancer patients Sponsor: Centre Leon Berard Phase: 2 Interested in offering this trial to suitable patients? Register Investigator Interest PD-1 blockade alone versus...
7 days ago • 2 min read
Oncology Hero 8 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials recently authorised in Europe. Breast density reduction with linzagolix or bilastine in premenopausal women at high risk of breast cancer: a phase II clinical trial. Sponsor: Consorci Mar Parc De Salut De Barcelona Phase: 2 Interested in offering this trial to suitable patients? Register Investigator Interest A phase 2 study to assess efficacy of induction...
14 days ago • 1 min read
Oncology Hero 8 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials recently authorised in Europe. RINGQUEST: Exploring Understudied Genitourinary Tumors with Sacituzumab Tirumotecan; a Single-arm, Basket, Phase II Study. Sponsor: Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard Phase: 2 Interested in offering this trial to suitable patients? Register Investigator Interest [18F] MC225 PET...
21 days ago • 1 min read
Oncology Hero 15 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials first authorised in Europe in the last week. Use of the Checkpoint inhibitor DOstarlimab in the endOmetrial cancer fertility-Sparing trEatment: CHOOSE study Sponsor: UZ Leuven Phase: 2 Interested in offering this trial to suitable patients? Register Investigator Interest Antibody-based PET imaging and treatment response in breast cancer treated with an...
about 1 month ago • 2 min read
Oncology Hero 6 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials first authorised in Europe in the last week. A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL) Sponsor: Oslo Universitetssykehus HF Phase: Not specified Interested in offering this trial to suitable patients? Register Investigator Interest A Phase 3 Randomized Study...
about 1 month ago • 1 min read
Oncology Hero 6 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials first authorised in Europe in the last week. Pilot study with Low-dose nivolumab in Advanced Neoplasms that are TMB-high Sponsor: UZ Brussel Phase: 2 Interested in offering this trial to suitable patients? Register Investigator Interest Randomized study evaluating the impact of an innovative and cooperative pathway integrating OncoGeriatric, pharmaceutical and...
about 2 months ago • 1 min read
Oncology Hero 10 new oncology trials approved in Europe Good morning, here is a concise selection of oncology and haematology trials first authorised in Europe in the last week. Sequence Strategy of Immuneoncology (IO-IO) vs IO-tyrosine kinase inhibitors (TKI) followed by TKI in metastatic renal cell carcinoma (mRCC): A randomized phase 3 study MeetURO and FICOG trial Sponsor: Fondazione IRCCS Istituto Nazionale Dei Tumori Phase: 3 Interested in offering this trial to suitable patients?...
about 2 months ago • 2 min read
In partnership with Oncology Updates — Aug 26 to Sep 2025 September delivered practice-relevant oncology updates worldwide — guideline shifts, pivotal trial readouts, new approvals, and high-impact AI tools. Below is a concise, clinician-first roundup. 🎗️ 🩺Lung cancer ESMO issues NSCLC guideline for early & locally advanced disease New recommendations standardize biomarker-driven multimodality care in stage I–III NSCLC, including integration of IO/targeted therapy in pathways. Read more...
about 1 year ago • 3 min read
Oncology Updates — August 2025 August 2025 delivered practice-relevant oncology updates worldwide — fresh guideline shifts, pivotal trial readouts, new approvals, diagnostics/devices, and high-impact AI tools. Below is a concise, clinician-first roundup, capped with a focused deep dive on the updated ASCO NSCLC guidelines. 🎗️ 💼 Earn for training the next generation of AI tools Medical Expert Hourly contract · Remote · $130–$180 per hour Apply here Physicians, Pathologists (Health Care and...
about 1 year ago • 2 min read
